<!doctype html>
<html class="no-js" lang="ja">
  <head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-55424252-12"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-55424252-12');
    </script>
    <meta charset="utf-8">
    <meta http-equiv="x-ua-compatible" content="ie=edge">
    <title>EP4拮抗薬 RQ-00000008 - ラクオリア創薬 - Ariafloat Stock</title>
    <meta name="description" content="ラクオリア創薬のEP4拮抗薬RQ-00000008に関する情報">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link rel="icon" type="image/png" href="../../img/boundcat-icon.png">
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/css/bootstrap.min.css" integrity="sha384-PsH8R72JQ3SOdhVi3uxftmaW6Vc51MKb0q5P2rRUpPvrszuE4W1povHYgTpBfshb" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/normalize/7.0.0/normalize.min.css">
    <link rel="stylesheet" href="../../css/main.css">
    <link rel="stylesheet" href="../css/raqualia.css">
    <!-- Google AdSense（ページ単位の広告） -->
    <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
    <script>
      (adsbygoogle = window.adsbygoogle || []).push({
        google_ad_client: "ca-pub-6825342955400774",
        enable_page_level_ads: true
      });
    </script>
    <!-- Google AdSense（ページ単位の広告） -->
  </head>
  <body id="top">
    <nav class="navbar navbar-expand-lg navbar-dark bg-dark">
      <div class="container">
        <a class="navbar-brand" href="https://stock.ariafloat.com/">Ariafloat Stock</a>
        <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
          <span class="navbar-toggler-icon"></span>
        </button>
        <div class="collapse navbar-collapse" id="navbarNav">
          <ul class="navbar-nav ml-md-auto">
            <li class="nav-item">
              <a class="nav-link" href="https://stock.ariafloat.com/raqualia/">Top</a>
            </li>
          </ul>
        </div>
      </div>
    </nav>
    <nav aria-label="breadcrumb">
      <div class="container">
        <ol class="breadcrumb breadcrumb-option">
          <li class="breadcrumb-item"><a href="https://stock.ariafloat.com/raqualia/">Top</a></li>
          <li class="breadcrumb-item active" aria-current="page">RQ-00000008</li>
        </ol>
      </div>
    </nav>
    <main role="main" style="text-align: center;">
      <h1 style="text-align: center;">EP4拮抗薬 RQ-00000008</h1>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container" style="max-width: 700px;">
          <h2 style="font-size: 1.7em">概要</h2>
          <p>2020年1月9日更新</p>
          <p class="text-left">EP4拮抗薬の「RQ-00000008」は、がん、疼痛、炎症など様々な適応症への利用が考えられている。</p>
          <div class="table-responsive">
            <table class="table" style="font-size: 0.9em">
              <tbody>
                <tr>
                  <th scope="row">化合物コード</th>
                  <td>RQ-00000008 [ラクオリア創薬]<br>AAT-008 [AskAt]<br>AT-019 [Elanco Animal Health]</td>
                </tr>
                <tr>
                  <th scope="row">主適応症</th>
                  <td>変形性関節症、自己免疫疾患など</td>
                </tr>
                <tr>
                  <th scope="row">開発状況</th>
                  <td>
                    動物薬：APIの製造工程と初期の製剤化作業の移管を開始（2019年初頭）
                  </td>
                </tr>
                <tr>
                  <th scope="row">導出状況</th>
                  <td>AskAt：全世界<br>以下は、AskAtによる再導出<br>Elanco Animal Health：動物薬領域<br>Arrys Therapeutics：がん免疫治療薬において中国・台湾を除く全世界<br>Ningbo NewBay MedicalTechnology：がん免疫治療薬において中国</td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container" style="max-width: 700px;">
          <h2 style="font-size: 1.7em">動物薬</h2>
          <p>2018年3月18日更新</p>
          <p class="text-left">
            AskAtは、Aratana Therapeuticsから契約一時金50万ドル、および、開発・販売に関わるマイルストンペイメント（達成一時金）を最大15.5百万ドル、純売上高に基づく1桁%台のロイヤルティを受け取る権利を有す。<br>
            ラクオリア創薬は、AskAtからEP4拮抗薬により得られる収益に対して適応症に応じて1桁%台～10%台のロイヤルティを受領する権利を有す。（※1）
          </p>
          <p>Aratanaの契約内容の参考（※2）<br>On February 28, 2018, the Company entered into an Exclusive License Agreement with AskAt (the “AskAt Agreement”) that granted the Company an exclusive global license for development and commercialization of compound AT-019 in the field of animal health. Under the terms of the AskAt Agreement, the Company will be required to pay an initial upfront license fee of $500. The Company will be required to pay AskAt remaining milestone payments associated with AT-019 of up to $15,500 upon the Company’s achievement of certain development/regulatory ($3,000) and commercial ($12,500) milestones, as well as tiered single digit royalties on the Company’s product sales, if any. The commercial milestones owed to AskAt under the AskAt Agreement begin to be triggered upon the first commercial sale with the final tier being owed to AskAt once annual net sales reach $100,000. Milestones, at the discretion of the Company, can be paid 50% in cash and 50% in a number of the Company’s shares as determined per the terms of the AskAt Agreement.</p>
          <p style='font-size: 0.8em'>
            ※1 <a href="https://www.raqualia.com/ja/news/ir/news-5771380324392788365.html" target="_blank" rel="nofollow">ラクオリア創薬「AskAt社と米国アラタナ社のライセンス契約締結のお知らせ」</a>より<br>
            ※2 <a href="http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12127606&type=HTML&symbol=PETX&companyName=Aratana+Therapeutics+Inc.&formType=10-K&dateFiled=2018-03-14" target="_blank" rel="nofollow">Aratana Therapeuticsの2017年度事業報告書</a>より
          </p>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container">
          <p>個人調査に基づくため、事業内容変更や誤認等により、本サイトの情報は“事実と異なる場合”があります。<br>そのため、投資判断に利用しないでください。また、本サイトは投資勧誘を目的としたものではありません。</p>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container">
          <!-- Google AdSense -->
          <div id="adsense" style="text-align: center;">
            <h6>スポンサーリンク</h6>
            <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
            <!-- レスポンシブ広告 -->
            <ins class="adsbygoogle"
                 style="display:block"
                 data-ad-client="ca-pub-6825342955400774"
                 data-ad-slot="1464182490"
                 data-ad-format="auto"
                 data-full-width-responsive="true"></ins>
            <script>
            (adsbygoogle = window.adsbygoogle || []).push({});
            </script>
          </div>
        </div>
      </section>
    </main>
    <footer class="text-muted" style="background-color: #F2F2F2;">
      <div class="container">
        <p class="float-right">
          <a class="none-a" href="#top">Page top</a>
        </p>
        <p><a class="none-toppage" href="https://stock.ariafloat.com/">&copy; Ariafloat Stock.</a>
        </p>
      </div>
    </footer>
    <script src="../../js/vendor/modernizr-3.5.0.min.js"></script>
    <script src="https://code.jquery.com/jquery-3.2.1.min.js" integrity="sha256-hwg4gsxgFZhOsEEamdOYGBf13FyQuiTwlAQgxVSNgt4=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.3/umd/popper.min.js" integrity="sha384-vFJXuSJphROIrBnz7yo7oB41mKfc8JzQZiCq4NCceLEaO4IHwicKwpJf9c9IpFgh" crossorigin="anonymous"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/js/bootstrap.min.js" integrity="sha384-alpBpkh1PFOepccYVYDB4do5UnbKysX5WZXm3XxPqe5iKTfUKjNkCk9SaVuEZflJ" crossorigin="anonymous"></script>
    <script src="../../js/plugins.js"></script>
    <script src="../../js/main.js"></script>
  </body>
</html>
